The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
NARC-1/PCSK9 and Its Natural Mutants
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The proteolytic activity of PCSK9 requires a catalytic triad of Asp186, His226, and Ser386.
“The proteolytic activity of PCSK9 requires a triad of residues (Asp 186, His 226 and Ser 386), which constitute the 'catalytic triad' of the protease.”
From PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1 (2008) · cites this paper as Benjannet et al, 2004
The Fig. 1 caption (page unavailable) identifies Asp, His, and Ser as PCSK9 active-site residues. The zymogen-processing results identify H226A as an active-site mutant that is not cleaved. Our copy does not identify the other two residues as Asp186 and Ser386 or establish that all three specified positions are required for proteolytic activity. (LLM, conf=0.83)
Experimental — accuracy not yet measuredPCSK9 is synthesized as an approximately 75 kDa proprotein (proPCSK9, P-form), and its N-terminal prodomain is removed by autocatalysis generating an approximately 65 kDa C-form that is secreted.
“PCSK9 is synthesized as an approximately 75 kDa proprotein (proPCSK9, P-form); the N-terminal prodomain is then removed by autocatalysis (Seidah et al, 2003;Benjannet et al, 2004) generating an approximately 65 kDa form (C-form) that is secreted into the extracellular milieu (Grozdanov et al, 2006).”
From PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1 (2008) · cites this paper as Benjannet et al, 2004
Mutation of one residue of the PCSK9 catalytic triad abolishes its proteolytic activity and its ability to undergo processing to the C-form.
“Mutation of one of these residues abolishes the proteolytic activity of PCSK9 and its ability to undergo processing to the C-form (Benjannet et al, 2004(Benjannet et al, , 2006;;McNutt et al, 2007).”
From PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1 (2008) · cites this paper as Benjannet et al, 2004
PCSK9 is synthesized as a proprotein zymogen in the ER that undergoes intramolecular autocatalytic cleavage to release the mature protein for transport out of the ER and for secretion.
“PCSK9 is synthesized as a proprotein zymogen in the ER that undergoes intramolecular autocatalytic cleavage to release the mature protein for transport out of the ER and for secretion115–117.”
From Pathways and Molecular Mechanisms Governing LDL Receptor Regulation (2025) · cites this paper as [117]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Michaely, P., Li, W.-P., Anderson, R. G. W., Cohen, J. C., & Hobbs, H. H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405242200 · Cited by 66
Flagged first, then by citations
Research works printed but not linked: 60
- Seidah, 1999, Brain Res., 848, 45, 10.1016/S0006-8993(99)01909-5 · DOI
- Zhou, 1999, J. Biol. Chem., 274, 20745, 10.1074/jbc.274.30.20745 · DOI
- Seidah, 1999, Proc. Natl. Acad. Sci. U. S. A., 96, 1321, 10.1073/pnas.96.4.1321 · DOI
- Sakai, 1998, Mol. Cell, 2, 505, 10.1016/S1097-2765(00)80150-1 · DOI
- Seidah, 2003, Proc. Natl. Acad. Sci. U. S. A., 100, 928, 10.1073/pnas.0335507100 · DOI · Paper page
- Seidah, 2002, Essays Biochem., 38, 79, 10.1042/bse0380079 · DOI
- Thomas, 2002, Nat. Rev. Mol. Cell. Biol., 3, 753, 10.1038/nrm934 · DOI
- Taylor, 2003, FASEB J., 17, 1215, 10.1096/fj.02-0831rev · DOI
- Roebroek, 1998, Development (Camb.), 125, 4863, 10.1242/dev.125.24.4863 · DOI
- Yang, 2001, Proc. Natl. Acad. Sci. U. S. A., 98, 13607, 10.1073/pnas.201524598 · DOI · Paper page
- Naureckiene, 2003, Arch. Biochem. Biophys., 420, 55, 10.1016/j.abb.2003.09.011 · DOI
- Jackson, 1997, Nat. Genet., 16, 303, 10.1038/ng0797-303 · DOI · Paper page
- Jackson, 2003, J. Clin. Investig., 112, 1550, 10.1172/JCI200318784 · DOI
- Abifadel, 2003, Nat. Genet., 34, 154, 10.1038/ng1161 · DOI · Paper page
- Rader, 2003, J. Clin. Investig., 111, 1795, 10.1172/JCI200318925 · DOI · Paper page
- Timms, 2004, Hum. Genet., 114, 349, 10.1007/s00439-003-1071-9 · DOI
- Leren, 2004, Clin. Genet., 65, 419, 10.1111/j.0009-9163.2004.0238.x · DOI
- Shioji, 2004, J. Hum. Genet., 49, 109, 10.1007/s10038-003-0114-3 · DOI
- Horton, 2003, Proc. Natl. Acad. Sci. U. S. A., 100, 12027, 10.1073/pnas.1534923100 · DOI · Paper page
- Maxwell, 2003, J. Lipid Res., 44, 2109, 10.1194/jlr.M300203-JLR200 · DOI · Paper page
- Dubuc, 2004, Arterioscler. Thromb. Vasc. Biol., 24, 1454, 10.1161/01.ATV.0000134621.14315.43 · DOI · Paper page
- Sakai, 1998, J. Biol. Chem., 273, 5785, 10.1074/jbc.273.10.5785 · DOI
- Brown, 1999, Proc. Natl. Acad. Sci. U. S. A., 96, 11041, 10.1073/pnas.96.20.11041 · DOI · Paper page
- Bergeron, 2003, Biochem. J., 373, 475, 10.1042/bj20021630 · DOI
- Conesa, 2003, Biochem. J., 370, 703, 10.1042/bj20021301 · DOI
- Benjannet, 2001, J. Biol. Chem., 276, 10879, 10.1074/jbc.M009899200 · DOI · Paper page
- Louie, 1991, Am. J. Hum. Genet., 48, 637
- Goldstein, 1983, Methods Enzymol., 98, 241, 10.1016/0076-6879(83)98152-1 · DOI
- Yoshimura, 1987, J. Biol. Chem., 262, 13299, 10.1016/S0021-9258(18)45201-5 · DOI
- Hatch, 1968, Adv. Lipid Res., 6, 1, 10.1016/B978-1-4831-9942-9.50008-5 · DOI
- Brissette, 1996, Biochem. J., 318, 841, 10.1042/bj3180841 · DOI
- Langer, 1972, J. Clin. Investig., 51, 1528, 10.1172/JCI106949 · DOI
- Lowry, 1951, J. Biol. Chem., 193, 265, 10.1016/S0021-9258(19)52451-6 · DOI
- Hopkins, 1983, J. Cell Biol., 97, 508, 10.1083/jcb.97.2.508 · DOI
- Jin, 2003, J. Clin. Investig., 111, 357, 10.1172/JCI16146 · DOI
- Gluschankof, 1994, EMBO J., 13, 2280, 10.1002/j.1460-2075.1994.tb06510.x · DOI
- Elagoz, 2002, J. Biol. Chem., 277, 11265, 10.1074/jbc.M109011200 · DOI · Paper page
- Reed, 1972, J. Biol. Chem., 247, 6970, 10.1016/S0021-9258(19)44681-4 · DOI
- Brayden, 1989, Br. J. Pharmacol., 98, 809, 10.1111/j.1476-5381.1989.tb14609.x · DOI
- Thyberg, 1985, Exp. Cell Res., 159, 1, 10.1016/S0014-4827(85)80032-X · DOI · Paper page
- Hortin, 1986, Biochem. Biophys. Res. Commun., 141, 326, 10.1016/S0006-291X(86)80372-2 · DOI
- Beisswanger, 1998, Proc. Natl. Acad. Sci. U. S. A., 95, 11134, 10.1073/pnas.95.19.11134 · DOI
- Ouguerrram, 2004, Arterioscler. Thromb. Vasc. Biol., 8, 1448, 10.1161/01.ATV.0000133684.77013.88 · DOI
- King-Underwood, 1991, Clin. Genet., 40, 17, 10.1111/j.1399-0004.1991.tb03064.x · DOI
- Gekle, 1995, Am. J. Physiol., 268, F899
- Kopfler, 1994, Circulation, 90, 1319, 10.1161/01.CIR.90.3.1319 · DOI
- Krieger, 1983, Cell, 33, 413, 10.1016/0092-8674(83)90423-3 · DOI
- Henrich, 2003, Nat. Struct. Biol., 10, 520, 10.1038/nsb941 · DOI
- Zhou, 1998, J. Biol. Chem., 273, 11107, 10.1074/jbc.273.18.11107 · DOI
- Benjannet, 1993, Biochem. J., 294, 735, 10.1042/bj2940735 · DOI
- De Bie, 1996, J. Cell Biol., 135, 1261, 10.1083/jcb.135.5.1261 · DOI
- Gregersen, 2001, J. Inherited Metab. Dis., 24, 189, 10.1023/A:1010319001722 · DOI
- Siezen, 1997, Protein Sci., 6, 501, 10.1002/pro.5560060301 · DOI · Paper page
- Soutar, 1992, J. Intern. Med., 231, 633, 10.1111/j.1365-2796.1992.tb01252.x · DOI
- Kunst, 1997, Nat. Genet., 15, 91, 10.1038/ng0197-91 · DOI
- Twisk, 2000, J. Clin. Investig., 105, 521, 10.1172/JCI8623 · DOI
- Tremblay, 2004, J. Lipid Res., 45, 866, 10.1194/jlr.M300448-JLR200 · DOI
- Wang, 1997, J. Biol. Chem., 272, 27644, 10.1074/jbc.272.44.27644 · DOI
- Maxwell, 2004, Proc. Natl. Acad. Sci. U. S. A., 101, 7100, 10.1073/pnas.0402133101 · DOI · Paper page
- Varret, 1999, Am. J. Hum. Genet., 64, 1378, 10.1086/302370 · DOI
Cited by
Sorted by citations
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Cohen, J., Pertsemlidis, A., Kotowski, I. K., Graham, R., Garcia, C. K., & Hobbs, H. H. (2005) · Nature Genetics · doi:10.1038/ng1509 · Cited by 1,381
Common variants at 30 loci contribute to polygenic dyslipidemia
Kathiresan, S., Willer, C. J., Peloso, G. M., Demissie, S., Musunuru, K., Schadt, E. E., Kaplan, L., Bennett, D., Li, Y., Tanaka, T., et al. (2009) · Nature Genetics · doi:10.1038/ng.291 · Cited by 1,364
Translating molecular discoveries into new therapies for atherosclerosis
Rader, D. J., & Daugherty, A. (2008) · Nature · doi:10.1038/nature06796 · Cited by 515
Self-citationA Spectrum of PCSK9 Alleles Contributes to Plasma Levels of Low-Density Lipoprotein Cholesterol
Kotowski, I. K., Pertsemlidis, A., Luke, A., Cooper, R. S., Vega, G. L., Cohen, J. C., & Hobbs, H. H. (2006) · The American Journal of Human Genetics · doi:10.1086/500615 · Cited by 517
Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer
Liu, X., Bao, X., Hu, M., Chang, H., Jiao, M., Cheng, J., Xie, L., Huang, Q., Li, F., & Li, C.-Y. (2020) · Nature · doi:10.1038/s41586-020-2911-7 · Cited by 490
Poirier, S., Mayer, G., Benjannet, S., Bergeron, E., Marcinkiewicz, J., Nassoury, N., Mayer, H., Nimpf, J., Prat, A., & Seidah, N. G. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m708098200 · Cited by 477
Self-citationLotta, L. A., Sharp, S. J., Burgess, S., Perry, J. R. B., Stewart, I. D., Willems, S. M., Luan, J., Ardanaz, E., Arriola, L., Balkau, B., et al. (2016) · JAMA · doi:10.1001/jama.2016.14568 · Cited by 394
Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): From bench to bedside
Bao, X., Liang, Y., Chang, H., Cai, T., Feng, B., Gordon, K., Zhu, Y., Shi, H., He, Y., & Xie, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01690-3 · Cited by 187
Kosenko, T., Golder, M., Leblond, G., Weng, W., & Lagace, T. A. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.421370 · Cited by 181
PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling
Kysenius, K., Muggalla, P., Mätlik, K., Arumäe, U., & Huttunen, H. J. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-0977-6 · Cited by 137
Regulation of PCSK9 by nutraceuticals
Momtazi, A. A., Banach, M., Pirro, M., Katsiki, N., & Sahebkar, A. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.03.023 · Cited by 131
Targeting PCSK9 for hypercholesterolemia
Norata, G. D., Tibolla, G., & Catapano, A. L. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-140025 · Cited by 127
Fedoseienko, A., Wijers, M., Wolters, J. C., Dekker, D., Smit, M., Huijkman, N., Kloosterhuis, N., Klug, H., Schepers, A., Willems van Dijk, K., et al. (2018) · Circulation Research · doi:10.1161/circresaha.117.312004 · Cited by 126
Jonas, M. C., Costantini, C., & Puglielli, L. (2008) · The EMBO Reports · doi:10.1038/embor.2008.132 · Cited by 119
Lalanne, F., Lambert, G., Amar, M. J. A., Chétiveaux, M., Zaïr, Y., Jarnoux, A.-L., Ouguerram, K., Friburg, J., Seidah, N. G., Brewer, H. B., et al. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m400396-jlr200 · Cited by 104
Self-citationDuff, C. J., Scott, M. J., Kirby, I. T., Hutchinson, S. E., Martin, S. L., & Hooper, N. M. (2009) · Biochemical Journal · doi:10.1042/bj20082407 · Cited by 99
Baum, S. J., Toth, P. P., Underberg, J. A., Jellinger, P., Ross, J., & Wilemon, K. (2017) · Clinical Cardiology · doi:10.1002/clc.22713 · Cited by 88
Scotti, E., Calamai, M., Goulbourne, C. N., Zhang, L., Hong, C., Lin, R. R., Choi, J., Pilch, P. F., Fong, L. G., Zou, P., et al. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.01716-12 · Cited by 81
Complexity of mechanisms among human proprotein convertase subtilisin-kexin type 9 variants
Dron, J. S., & Hegele, R. A. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000386 · Cited by 72
Butkinaree, C., Canuel, M., Essalmani, R., Poirier, S., Benjannet, S., Asselin, M.-C., Roubtsova, A., Hamelin, J., Marcinkiewicz, J., Chamberland, A., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.647180 · Cited by 53
Self-citationPCSK9 acts as a chaperone for the LDL receptor in the endoplasmic reticulum
Strøm, T. B., Tveten, K., & Leren, T. P. (2014) · Biochemical Journal · doi:10.1042/bj20130930 · Cited by 48
Zhao, X.-S., Wu, Q., Peng, J., Pan, L.-H., Ren, Z., Liu, H.-T., Jiang, Z.-S., Wang, G.-X., Tang, Z.-H., & Liu, L.-S. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2016.6055 · Cited by 46
Pathways and Molecular Mechanisms Governing LDL Receptor Regulation
Schmidt, H. M., Jarrett, K. E., de Aguiar Vallim, T. Q., & Tarling, E. J. (2025) · Circulation Research · doi:10.1161/circresaha.124.323578 · Cited by 33
PCSK9 inhibition to reduce cardiovascular disease risk: recent findings from the biology of PCSK9
Tavori, H., Giunzioni, I., & Fazio, S. (2015) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000137 · Cited by 30
Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction
Tavori, H., Melone, M., & Rashid, S. (2014) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2014.954551 · Cited by 21
Mazura, A. D., & Pietrzik, C. U. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041268 · Cited by 9
Zheng, X., Yuan, W., Li, L., Ma, H., Zhu, M., Li, X., & Feng, X. (2025) · European Journal of Medical Research · doi:10.1186/s40001-025-02937-1 · Cited by 9
Metadata
- Authors
- Benjannet, S., Rhainds, D., Essalmani, R., Mayne, J., Wickham, L., Jin, W., Asselin, M.-C., Hamelin, J., Varret, M., Allard, D., Trillard, M., Abifadel, M., Tebon, A., Attie, A. D., Rader, D. J., Boileau, C., Brissette, L., Chrétien, M., Prat, A., & Seidah, N. G.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2004-11
- Volume
- 279
- Issue
- 47
- Pages
- 48865-48875
- ISSN
- 0021-9258
- Cited by
- 587
- References
- 1
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review